Uveal Melanoma Diagnosis and Treatment Strategies

Uveal melanoma is the most common primary intraocular malignancy and poses significant challenges due to its proclivity for early dissemination, particularly to the liver. Diagnosis is established by comprehensive ophthalmic examination, imaging modalities such as ultrasound biomicroscopy, optical coherence tomography and magnetic resonance imaging, and, where indicated, fine-needle aspiration or biopsy to obtain cytogenetic and molecular data. Characteristic mutations in GNAQ, GNA11, BAP1 and SF3B1 underpin prognostic classification and guide risk stratification. Primary tumours are treated by globe-preserving radiotherapy or enucleation, achieving excellent local control. However, nearly half of patients develop metastatic disease for which conventional systemic therapies yield limited benefit. Liver-directed interventions, including isolated hepatic perfusion and embolisation, modestly prolong progression-free survival but do not substantially improve long-term outcomes. Immune checkpoint inhibitors have shown disappointing responses, prompting exploration of novel approaches. Recent preclinical work has identified synthetic-lethal vulnerabilities in oncogenic signalling pathways and opportunities to modulate the tumour microenvironment. Emerging strategies include targeted inhibition of MAPK effectors, nanodelivery of epigenetic and metabolic inhibitors combined with immunotherapy, and the use of high-resolution transcriptomics to uncover prognostic immune cell subsets. Together, these advances offer a roadmap for more precise diagnosis and more effective, personalised treatments for uveal melanoma.

Research from Nature Portfolio

Recent studies have uncovered a synthetic-lethal dependency in uveal melanoma cells harbouring GNAQ or GNA11 mutations. Genome-scale CRISPR screening and in vivo validation demonstrated that loss of the inositol-metabolising phosphatase INPP5A leads to accumulation of inositol trisphosphate, elevated cytosolic calcium and p53-dependent apoptosis, identifying INPP5A as a promising therapeutic target for mutant GNAQ/GNA11-driven tumours. Another investigation employed a genetically engineered mouse model expressing hyperactive GNAQ in endothelial cells to mimic tumour-associated coagulopathy. Transcriptomic analysis revealed hyperactivation of mitogen-activated protein kinase signalling and showed that trametinib, a MEK inhibitor, effectively suppressed vascular tumour growth, prevented coagulopathy and improved survival, supporting MAPK pathway blockade as a rational approach to both tumour control and management of paraneoplastic complications.

Uveal Melanoma Diagnosis and Treatment Strategies publication trend

The graph below shows the total number of articles in uveal melanoma diagnosis and treatment strategies across all publications each year (not limited to Nature Index journals).

Technical terms

Uveal melanoma: A malignancy arising from melanocytes in the uveal tract of the eye, characterised by a high risk of liver metastasis.

Synthetic lethality: A genetic interaction in which simultaneous impairment of two genes leads to cell death, while disruption of either one alone is tolerated.

Pyroptosis: A form of programmed cell death associated with inflammatory signalling and characterised by rapid cell lysis.

Progression-free survival: The period during which a patient’s disease does not worsen, used as an efficacy endpoint in clinical trials.

Nanoparticle: A microscopic carrier system designed to deliver therapeutic agents to specific tissues or cells with controlled release.

References

1. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). Journal of Clinical Oncology (2023).
2. INPP5A phosphatase is a synthetic lethal target in GNAQ and GNA11-mutant melanomas. Nature Cancer (2024).
3. MEK inhibition reduced vascular tumor growth and coagulopathy in a mouse model with hyperactive GNAQ. Nature Communications (2023).
4. Single-cell characterization of macrophages in uveal melanoma uncovers transcriptionally heterogeneous subsets conferring poor prognosis and aggressive behavior. Experimental & Molecular Medicine (2023).
5. Co‐delivery Nano System of MS‐275 and V‐9302 Induces Pyroptosis and Enhances Anti‐Tumor Immunity Against Uveal Melanoma. Advanced Science (2024).